HIV prevention

Stable3 articles3 sourcesDernière mise à jour: il y a 7 heures

Sujets associéslenacapavir PrEP public health US foreign aid USAID funding cuts global health Aids 2026 Conference

Derniers articles

US Aid Cuts Threaten Global HIV Prevention Innovations

Experts at the Aids 2026 Conference in Rio de Janeiro warn that US foreign aid cuts, particularly the dissolution of USAID, are hindering global access to new HIV prevention innovations like lenacapavir, jeopardizing efforts to reduce new infections, especially in vulnerable populations.

Guardian World

3 min de lecture

Lenacapavir: A Long-Acting HIV Prevention Drug Faces Access Challenges

En développement

Santé·23/07/2026Résumé IA

Lenacapavir: A Long-Acting HIV Prevention Drug Faces Access Challenges

Lenacapavir, an injectable HIV prevention drug requiring only two doses annually, offers a significant advantage over daily pills by improving adherence. Despite its potential, access remains limited due to high costs and exclusion from supply deals in several vulnerable regions, including parts of Latin America.

Deutsche Welle

4 min de lecture

France: PrEP for HIV Prevention Underutilized, Advocates Urge Wider Access

En développement

Santé·01/06/2026Résumé IA

France: PrEP for HIV Prevention Underutilized, Advocates Urge Wider Access

France's National Council for AIDS and Viral Hepatitis (CNS) laments the underutilization of PrEP, an effective HIV prevention method, calling for public authorities to expand access beyond its current primary users, predominantly gay men.

France Info

2 min de lecture